Last reviewed · How we verify

NCT02516111

Comparative Evaluation of Autologous PRF, 1% Alendronate and 1.2% Atorvastatin Gel in Treatment of 2/3-walled Intrabony Defects in Chronic Periodontitis Subjects: a Randomized Controlled Clinical Trial

Completed Phase 2/Phase 3 Last updated 4 August 2015
What this trial tests

Phase 2/Phase 3 trial testing Open flap debridement (OFD) in Chronic Periodontitis in 120 participants. Completed in 1 May 2015.

Timeline
1 September 2014
Primary endpoint
1 May 2015
1 May 2015

Quick facts

Lead sponsorGovernment Dental College and Research Institute, Bangalore
PhasePhase 2/Phase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment120
Start date1 September 2014
Primary completion1 May 2015
Estimated completion1 May 2015

Drugs / interventions tested

Conditions studied

Sponsor

Government Dental College and Research Institute, Bangalore

Who can join

Adults 30 to 50, female only, with Chronic Periodontitis. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The present study is designed as a single-centre, randomized, controlled clinical trial to evaluate and compare the clinical efficacy of autologous PRF, 1% alendronate (ALN) and 1.2% atorvastatin (ATV) gel placement with open flap debriedement in treatment of intrabony defects in patients with chronic periodontitis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Periodontitis

Currently open trials in the same condition.

Other Government Dental College and Research Institute, Bangalore trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02516111.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing